Nicky Lawrence
@nickymitchell
Followers
371
Following
2K
Media
50
Statuses
735
Medical oncologist, interested in genitourinary malignancies and clinical trial design
Auckland, New Zealand
Joined March 2009
Very inspiring AoNZ concept development workshop today! Bring on #ACORD26 @MartinStockler
0
1
2
1/2 Disitimab Vedotin & toripalimab beating platinum chemotherapy in 1st line UC in HER2 +ves. HRs for PFS/OS =0.36/0.56 respectively. RR and CR rate of 76% & 5% respectively. Tox related discontinuation in 12 vs 10% respectively. Working across all subsets #ESMO25 @OncoAlert
1
44
96
Outstanding discussion by @AzadOncology on #PSMAaddition at #ESMO25 👉highlighting the need for a personalized approach in mHSPC #ProstateCancer 👉 pt selection, toxicity vigilance, & that not all pts need Lu-177 or 6 cycles 👉precision, not over-treatment. @OncoAlert @UroToday
1
33
59
Outstanding discussion of the ENZARAD results by @Prof_Nick_James on why there is a difference in outcomes in the ENZARAD vs Stampede trial #ESMO25 @OncoAlert @urotoday @PCF_Science
0
28
36
Fantastic talk by @DrPaulNguyen #ESMO25 👉result of ph3 Enzarad trial👉Addition of ENZA to ADT + radiation did not improve MFS in all high risk localized, the primary endpoint. However, node+ on CT/MRI pts derived benefit, like Stampede trial @OncoAlert @urotoday @PCF_Science
4
52
96
Incredible data from EMBARK demonstrating OS benefit of ENZA + ADT for high risk BCR. @myESMO #ESMO25 @OncoAlert
2
8
25
Breaking news from #ESMO25👉Improved OS in high risk biochemical recurrent #ProstateCancer on with ENZA+ADT vs ADT alone, HR: 0.59 (no OS benefit with ENZA monotherapy), 👏wonderful news for our pts👉congrats @SFreedlandMD @nealshore & the team. @OncoAlert @urotoday @PCF_Science
4
61
127
Carefully done #RAMPART adjuvant trial for durvalumab in #kidneycancer, showing disease free survival benefit. #ESMO25 @myESMO #ESMOAmbassadors @OncoAlert
2
9
22
📣 #ESMO2025: n=565 🇬🇧🇪🇸🇦🇺🇫🇷 RAMPART RCT; Durvalumab + tremelimumab 📈boosts DFS in resected RCC #kidneycancer (HR 0.65, 2-yr 84% vs 78%), esp. in leibovich high-risk pts (HR 0.52, 81% vs 67%). G3+ AES 8% monitoring versus 40% with durva+treme. OS data eagerly awaited! #kcsm
0
9
15
Clean trial of lenvatinib-everolimus vs cabozantinib in refractory #kidneycancer from @OncHahn @MDAndersonNews
#ESMO25 #ESMOAmbassadors @OncoAlert
3
16
40
This is so cool. Imagine a world of 65% pT0 CR rates for muscle invasive bladder cancer. This is for cis ineligible but will there be scope creep? Looking forward to EV304 cis eligible. #esmo25 @OncoAlert #amazing
The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25
2
20
59
1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery
5
138
341
Phase 1 trial of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced #ProstateCancer. Presentation by Jose Avitia, MD. #ESMO25 written coverage by @RKSayyid > https://t.co/NitQrmpqQA
@UAUrology @myESMO @neerajaiims
1
6
9
Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science
6
90
176
The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future
7
62
136
A historic moment at #ESMO25. Dr Christof Vulsteke presents #KEYNOTE905: Periop EV + Pembro in cisplatin-ineligible MIBC: ✅ EFS HR 0.40 ✅OS HR 0.50 ✅pCR 57% vs 9% Four rounds of applause from a packed room 👏 @OncoAlert @myESMO @Uromigos @urotoday
2
19
40
Renal cancer 1st line randomised PII KMUA3B #ESMO25 with lenavatinib/pembro as the control (hard to beat with RR>80%). Len/pem/belzutifan showed good PFS (HR0.45) ✅ which may lead to a positive RIII (LS12) which is ongoing. TIGIT 🛑 & LAG3 🛑 were disappointing again @OncoAlert
1
37
67
First @ANZUPtrials Ideas Generation Workshop in New Zealand - putting the NZ into ANZUP! Thanks to @nickymitchell and @DrCraigGedye for the warm welcome.
0
4
8
#ENZAMET @ANZUPtrials @TrialsCentre #ASCO25 ✅ 50% survival at 8yr vs 40% - sustained, all subgroups ✅ non-#ProstateCancer deaths same in both arms: removes doubts of long term safety and benefit re competing causes of death ✅ undetectable PSA is good; more likely with enza
8-year outcomes of enzalutamide vs a non-steroidal anti-androgen for metastatic, hormone-sensitive #ProstateCancer (ENZAMET; ANZUP 1304). Presented by Alison Zhang, MD, PhD @Sydney_Uni. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/5UUNf83t4i
@ASCO
0
15
36